

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/087,355	03/01/2002	Richard C. Boucher JR.	5470.250DV	3423
20792	7590 09/10/2002			
MYERS BIG	GEL SIBLEY & SAJ	OVEC	EXAMI	NER
PO BOX 374	28		WANG, SH	ENGILIN
RALEIGH, N	IC 27627		WANG, SII	ENGJON
			ART UNIT	PAPER NUMBER
-			1617	
		·	DATE MAILED: 09/10/2002	C

Please find below and/or attached an Office communication concerning this application or proceeding.

<i>-</i> · · · ·	Application No.	Applicant(s)
	10/087,355	BOUCHER, RICHARD C.
Office Action Summary	Examiner	Art Unit
	Shengjun Wang	1617
The MAILING DATE of this communication Period for Reply	on appears on the cover sheet v	vith the correspondence address
A SHORTENED STATUTORY PERIOD FOR F THE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 of after SIX (6) MONTHS from the mailing date of this communicat - If the period for reply specified above is less than thirty (30) days - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, by - Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	CION. CFR 1.136(a). In no event, however, may a tion. s, a reply within the statutory minimum of the period will apply and will expire SIX (6) MC y statute, cause the application to become A	a reply be timely filed irty (30) days will be considered timely. DNTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed of	n	
2a) This action is FINAL . 2b)	This action is non-final.	
3) Since this application is in condition for closed in accordance with the practice understood of Claims		
4)⊠ Claim(s) <u>1,14-21 and 31-50</u> is/are pendi	ng in the application.	
4a) Of the above claim(s) is/are wi	thdrawn from consideration.	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		,
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1, 14-21 and 31-50</u> are subject Application Papers	to restriction and/or election re	quirement.
9) The specification is objected to by the Exa	aminer.	
10) The drawing(s) filed on is/are: a) □		the Examiner.
Applicant may not request that any objection		
11) The proposed drawing correction filed on	is: a) approved b)	disapproved by the Examiner.
If approved, corrected drawings are required	d in reply to this Office action.	
12) The oath or declaration is objected to by t	he Examiner.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for f	foreign priority under 35 U.S.C.	. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority docu	uments have been received.	•
2. Certified copies of the priority docu	uments have been received in a	Application No
3. Copies of the certified copies of the application from the Internation* See the attached detailed Office action for	nal Bureau (PCT Rule 17.2(a)).	
14) Acknowledgment is made of a claim for do	omestic priority under 35 U.S.C	c. § 119(e) (to a provisional application
a) The translation of the foreign languages 15) Acknowledgment is made of a claim for do	~ '	
Attachment(s)		
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-9-8) Information Disclosure Statement(s) (PTO-1449) Paper N	48) 5) Notice o	v Summary (PTO-413) Paper No(s) f Informal Patent Application (PTO-152)



Application/Control Number: 10/087,355

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

- 1. This application contains claims directed to the following patentably distinct species of the claimed invention:
- 2. A) Treated subject afflicted with different diseases: cystic fibrosis, claim 15; chronic bronchitis, claim 16; primary or secondary ciliary dyskinesia, claim 17; pneumonia, claim 18; and sinusitis, claim 19.
- 3. B) Administering step: inhalation, claim 20; transbronchoscopic lavage, claim 21.
- 4. C) The salt or salts employed in the method: potassium nitrate, claim 45; potassium gluconate, claim 46; potassium iodide, claim 47; potassium bromide, claim 48; potassium phosphate, claim 49; and potassium bicarbonate, claim 50.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from each of the given groups for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 1, 14, 31-44 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after

Application/Control Number: 10/087,355

Art Unit: 1617

the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (703) 308-4554. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Examiner

Shengjun Wang

September 5, 2002